Fast weight loss injections: what the trial data tells you

What the trial results show, and what they don't

SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across 72 weeks. Participants on tirzepatide 15mg lost an average of around 20–21% of their body weight. The STEP 1 trial, also published in the NEJM, showed semaglutide 2.4mg producing roughly 15% average weight reduction over 68 weeks. Those are striking figures by any clinical standard.

What neither trial shows is rapid week-one transformation. Treatment starts at a low dose (2.5mg for tirzepatide, 0.25mg for Wegovy) because the first pen's job is to let your system adjust, not to deliver peak effect. The appetite-suppressing and gastric-slowing effects build as the dose is titrated, typically every four weeks under prescriber guidance. Early weeks often bring noticeable changes in hunger and portion size before the scales move significantly. That is the mechanism working, not it failing.

The SURMOUNT-5 head-to-head trial, published in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks, a useful comparison if you are choosing between the two. If you want more detail on how the timelines compare, our page on how fast weight loss injections work covers the week-by-week picture, including what to realistically expect at each stage of titration.

Why 'fastest' is not quite the right question to ask

Speed of loss varies between individuals based on starting weight, dose tolerated, lifestyle factors and metabolic differences. Someone who cannot tolerate a higher dose because of nausea will titrate more slowly than the trial average. Someone who changes very little about their diet may lose less overall, even on the same medicine.

Clinically, the more useful questions are: which injection is licensed for my situation, which do I tolerate, and can I sustain it? Comparing the fastest-acting options gives a fuller breakdown. The NICE appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing should be reviewed, a reminder that response is monitored, not assumed.

Both Mounjaro and Wegovy are Black Triangle medicines, meaning they carry additional MHRA monitoring. That is not a reason to avoid them; it is a reason to use them through a service that reviews your progress, flags concerns, and escalates when needed. Chasing the absolute quickest result by sourcing these injections outside a legitimate clinical pathway carries real risks, see the counterfeit warning below.

Side effects that affect pace, and what to do about them

The most common reason people slow their titration, or stay longer at a lower dose, is gastrointestinal side effects. Nausea, vomiting, diarrhoea and constipation are reported most frequently at the start of treatment and after dose steps upward. In most cases they are mild to moderate and settle within days to a couple of weeks as the body adjusts.

Staying well hydrated matters. Eating smaller, lower-fat meals helps. Protein intake and some resistance activity are worth maintaining throughout, because a proportion of weight lost on any caloric deficit includes muscle mass. A prescriber can advise on pacing if side effects are affecting your daily life, that is a clinical conversation, not a problem to push through alone.

On safety: in January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines specifically flagging acute pancreatitis. Severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention, not waiting to see if it passes. Any suspected side effect can be reported at the MHRA Yellow Card scheme. Injection-site reactions are also possible; rotating the site each week (abdomen, thigh or upper arm) reduces them.

Getting these medicines safely, and what to be wary of

Both tirzepatide and semaglutide are prescription-only medicines. The only lawful route to them is a prescription issued after proper clinical assessment. The MHRA has warned repeatedly about counterfeit pens sold online, fake tirzepatide pens have been seized in the UK in large quantities, and the harm from unverified products is real. A useful check: any online pharmacy dispensing these medicines should appear on the GPhC pharmacy register. If it doesn't, don't order.

There is a page on how to get weight loss injections through the correct clinical pathway if you want a step-by-step account of what that process involves. For a broader overview of which weight loss injections are available in the UK and how they compare, that covers the full landscape.

If you order through nume and a prescriber approves your treatment, your medication arrives the next working day via DPD in plain, unbranded packaging, tracked to your door. One price covers consultation, prescription, delivery and 7-day aftercare; there is no subscription and every repeat is clinically reviewed before it goes out. Cost context varies by dose and provider; our treatment page shows current pricing transparently.

If you have questions before you start, or want to understand which option fits your circumstances, you can read about the Waygo weight loss injection to see whether it suits your situation. When you're ready, speak to our prescribers through a free consultation, no obligation, no algorithm.